These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23833377)

  • 1. Perforated duodenal ulcer: a rare complication of deferasirox in children.
    Yadav SK; Gupta V; El Kohly A; Al Fadhli W
    Indian J Pharmacol; 2013; 45(3):293-4. PubMed ID: 23833377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric ulcer in a child treated with deferasirox.
    Bauters T; Mondelaers V; Robays H; Hunninck K; de Moerloose B
    Pharm World Sci; 2010 Apr; 32(2):112-3. PubMed ID: 20063122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced duodenal perforation in the paediatric patient with thalassemia major, an unreported side effect of iron- chelating agent: A case report.
    Shakir FTZ; Sultan R; Siddiqui R; Shah MZ; Javed A; Maryam N
    J Pak Med Assoc; 2022 Jul; 72(7):1441-1443. PubMed ID: 36156578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perforated Duodenal Ulcer Associated with Deferasirox in a Child with β-Thalassemia Major.
    Zahra A; Ragab A; Al-Abboh H; Ismaiel A; Adekile AD
    Hemoglobin; 2021 Sep; 45(5):335-337. PubMed ID: 34979847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perforated duodenal ulcer secondary to deferasirox use in a child successfully managed with laparoscopic drainage: A case report.
    Alshehri A; Alsinan TA
    World J Clin Cases; 2022 Dec; 10(34):12775-12780. PubMed ID: 36579108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox causing duodenal ulcer leading to upper gastrointestinal bleed and hemorrhagic shock in a child with beta-thalassemia major.
    Tresa A; Shankar GH; Sarangi BU; Walimbe A
    Indian J Pharmacol; 2023; 55(5):335-337. PubMed ID: 37929413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?
    Vlachaki E; Chatzinikolaou K; Bekiari E; Klonizakis F; Tsapas A
    Angiology; 2011 May; 62(4):346-8. PubMed ID: 21306999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
    Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
    Yacobovich J; Stark P; Barzilai-Birenbaum S; Krause I; Pazgal I; Yaniv I; Tamary H
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):564-7. PubMed ID: 20733517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with acute perforated duodenal ulcer in a West African population.
    Nuhu A; Kassama Y
    Niger J Med; 2008; 17(4):403-6. PubMed ID: 19048755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
    Masera N; Rescaldani C; Azzolini M; Vimercati C; Tavecchia L; Masera G; De Molfetta V; Arpa P
    Haematologica; 2008 Jan; 93(1):e9-10. PubMed ID: 18166775
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.
    Dell'Orto VG; Bianchetti MG; Brazzola P
    J Clin Pharm Ther; 2013 Dec; 38(6):526-7. PubMed ID: 23981248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
    Ford JM; Rojkjaer L
    Haematologica; 2008 Jun; 93(6):e49; discussion e50. PubMed ID: 18515872
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
    Rheault MN; Bechtel H; Neglia JP; Kashtan CE
    Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perforated duodenal ulcer presenting with massive hematochezia in a 30-month-old child.
    Lee NM; Yun SW; Chae SA; Yoo BH; Cha SJ; Kwak BK
    World J Gastroenterol; 2009 Oct; 15(38):4853-5. PubMed ID: 19824124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy.
    Vill K; Müller-Felber W; Teusch V; Blaschek A; Gerstl L; Huetker S; Albert MH
    Neuromuscul Disord; 2016; 26(4-5):322-5. PubMed ID: 27068298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
    Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
    Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
    Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH
    Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.